MedPath

Lofexidine

Generic Name
Lofexidine
Brand Names
Lucemyra
Drug Type
Small Molecule
Chemical Formula
C11H12Cl2N2O
CAS Number
31036-80-3
Unique Ingredient Identifier
UI82K0T627
Background

Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.

Indication

Lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.

Opioid withdrawal syndrome is a debilitating manifestation of opioid dependence. This condition is extremely unpleasant lasting several days with some of the main features being abdominal pain, nausea, diarrhea, mydriasis, lacrimation, and piloerection. These symptoms are often observed after abrupt reductions in the opioid dose and can be resolved by re-administration of the opioid.

Associated Conditions
Abrupt opioid withdrawal
Clinical Trials
Related News

FDA Approves Roxybond 10mg for Severe Pain with Abuse-Deterrent Technology

• The FDA has approved Protega Pharmaceuticals' Roxybond 10mg for managing severe pain when alternative treatments are inadequate. • Roxybond is the first FDA-approved immediate-release oxycodone formulation with abuse-deterrent technology designed to reduce misuse via intranasal and intravenous routes. • The SentryBond technology in Roxybond makes the tablet more difficult to manipulate, potentially reducing abuse while providing pain relief. • Roxybond's approval addresses the critical need for safer opioid pain management options amid the ongoing opioid crisis, with over 108,000 drug overdose deaths reported.

Novel NaV1.8 Inhibitors Lead Wave of Non-Opioid Pain Treatments as Industry Tackles Opioid Crisis

• Vertex Pharmaceuticals' VX-548 (suzetrigine) demonstrates significant pain reduction in Phase 3 trials, advancing toward FDA approval as the first new acute pain medicine class in over 20 years. • The opioid epidemic continues to escalate with US drug overdose deaths exceeding 100,000 in 2023, driving urgent need for non-addictive pain management alternatives. • Latigo Biotherapeutics enters the non-opioid pain treatment space with $135 million Series A funding, developing NaV1.8 inhibitors to potentially rival Vertex's suzetrigine.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy